Reduction of Platinum(IV) Prodrug Hemoglobin Nanoparticles with Deeply Penetrating Ultrasound Radiation for Tumor-Targeted Therapeutically Enhanced Anticancer Therapy

Angew Chem Int Ed Engl. 2023 May 22;62(22):e202301074. doi: 10.1002/anie.202301074. Epub 2023 Apr 19.

Abstract

The development of PtIV prodrugs that are reduced into the therapeutically active PtII species within the tumor microenvironment has received much research interest. In order to provide spatial and temporal control over the treatment, there is a high demand for the development of compounds that could be selectively activated upon irradiation. Despite recent progress, the majority of PtIV complexes are excited with ultraviolet or blue light, limiting the use of such compounds to superficial application. To overcome this limitation, herein, the first example of PtIV prodrug nanoparticles that could be reduced with deeply penetrating ultrasound radiation is reported, enabling the treatment of deep-seated or large tumors. The nanoparticles were found to selectively accumulate inside a mouse colon carcinoma tumor upon intravenous injection and were able to eradicate the tumor upon exposure to ultrasound radiation.

Keywords: Bioinorganic Chemistry; Medicinal Inorganic Chemistry; Metals in Medicine; Platinum; Ultrasound Radiation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Cell Line, Tumor
  • Mice
  • Nanoparticles*
  • Neoplasms* / drug therapy
  • Platinum / therapeutic use
  • Prodrugs* / pharmacology
  • Prodrugs* / therapeutic use
  • Tumor Microenvironment

Substances

  • Prodrugs
  • Platinum
  • Antineoplastic Agents